Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The calcium channel blocker controversy.

N M Kaplan1

  • 1Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, 75235-8899, USA.

Hypertension Research : Official Journal of the Japanese Society of Hypertension
|June 1, 1996
PubMed
Summary

The safety concerns surrounding calcium channel blockers (CCBs) are largely unfounded for current hypertension treatments. Long-acting CCBs, unlike older short-acting versions, do not pose the same risks to patients, especially those with a history of myocardial infarction (MI).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Mail.

Postgraduate medicine·2016
Same author

Microbiology of wound infection after caesarean section in a Jordanian hospital.

Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit·2006
Same author

What is the impact of systolic blood pressure lowering on preventing cardiovascular events?

Journal of human hypertension·2004
Same author

The place of diuretics in preventing cardiovascular events.

Journal of human hypertension·2004
Same author

Use of thermonuclease testing to identify Staphylococcus aureus by direct examination of blood cultures.

Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit·2004
Same author

Executive summaries on hypertension II. Choices of initial drug therapy.

Drugs of today (Barcelona, Spain : 1998)·2004

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • A recent case-control study linked short-acting calcium channel blockers (CCBs) to increased risk of myocardial infarction (MI) in hypertensive patients.
  • Older studies indicated elevated mortality rates with high-dose, short-acting nifedipine in post-MI patients.

Purpose of the Study:

  • To address the controversy surrounding CCB safety in hypertension treatment.
  • To differentiate the risks associated with short-acting CCBs from the safety profile of long-acting CCBs.

Main Methods:

  • Review of a case-control study on CCB use and MI in hypertensive patients.
  • Re-evaluation of historical studies on short-acting nifedipine and post-MI mortality.
  • Analysis of current clinical practices regarding CCB formulations.

Related Experiment Videos

Main Results:

  • The identified risks of short-acting CCBs are linked to specific formulations and dosages not reflective of current therapeutic standards.
  • The danger of massive doses of short-acting nifedipine in post-MI patients is considered irrelevant to contemporary clinical practice.
  • The safety concerns extrapolated from older studies do not apply to the current use of long-acting CCBs in managing hypertension.

Conclusions:

  • The controversy regarding CCB safety is largely irrational and unfortunate.
  • Current long-acting CCBs are safe and effective for hypertension management.
  • Clinical decisions should differentiate between short-acting and long-acting CCB formulations.